Navigation Links
Amgen Highlights Data to be Presented at ASH
Date:11/30/2009

THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009).

"We are excited to present data on the safety and efficacy of Nplate in the pediatric setting for the first time," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "Similar to adults who have chronic ITP, children living with this disease have limited treatment options. We will also present data from a large global study of Nplate as a treatment for thrombocytopenia in patients with MDS."

SELECTED ABSTRACTS OF INTEREST

Abstracts are available and can be viewed on the ASH website at www.hematology.org. Identified below are selected abstracts of interest on Amgen research. Updated data will be presented at the meeting.

Nplate

Researchers will present five year follow-up results from the ongoing, open-label extension study on the long-term safety and efficacy of Nplate in adult patients with chronic ITP. Chronic ITP is a serious autoimmune disorder characterized by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. These results support previously presented data which illustrated Nplate sustained platelet counts with extended treatment. Additionally, data regarding pediatric treatment of ITP will be
'/>"/>

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
10. Call for Applications: The Amgen Award for Science Teaching Excellence
11. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... DALLAS , September 19, 2014 ... Market by Equipment Type (Benchtop, Mobile, Industrial, & ... Others), Technology (Tray-style, Manifold, & Rotary) & Geography ... by MarketsandMarkets, defines and segments the lyophilization market ... regions with analyses and projections of the market ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... , , FARMINGDALE, N.Y., Jan. 11 Misonix, ... invasive ultrasonic medical device technology, which in Europe is ... other acute health conditions, has entered into a new, ... in Lima, Peru, for the distribution of the SonaStar(TM) ...
... , BETHESDA, Md., Jan. 11 Spherix Inc. (Nasdaq: ... a provider of technical and regulatory consulting services to food, ... Dr. Robert Lodder, will be presenting at the Annual OneMedPlace ... Drake Hotel in San Francisco, CA. Dr. Lodder will ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Peru 2Misonix Announces New Distribution Agreement for Peru 3Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 2Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 3
(Date:9/20/2014)... The festival season is coming soon. The high-end fashion designer ... cocktail dresses . A lot of sophisticated women like its ... new promotion for its high quality clothes. Now, each of ... 20 to 71 percent off. , The company’s cocktail ... provided in many fashionable colors. Mary, the company’s sales manager, ...
(Date:9/20/2014)... September 20, 2014 Recently, Best ... site, has launched its new website. The new ... of popular hosting products for customers. Here, people ... make a purchasing decision. Also, it has recommended ... , One of the great web hosting ...
(Date:9/20/2014)... September 20, 2014 Plumbing construction ... out of 5, indicating a moderately favorable purchasing environment ... score reflects current and future pricing trends that will ... prices. Other factors that negatively affect buyer power are ... construction and the moderate switching costs. Buyers benefit, however, ...
(Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
(Date:9/19/2014)... (PRWEB) September 20, 2014 Nearly 780 ... of Common Pleas where a meeting took place to ... complaints pending in the court’s mass tort program. ... meet this past week at the Complex Litigation Center ... consolidated for pretrial proceedings. The Risperdal lawsuits filed against ...
Breaking Medicine News(10 mins):Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4
... the future may be painless and noninvasive, thanks to smart ... test for skin cancer, patients today must endure doctors cutting ... lab and anxiously awaiting the results. Using laser microscopes that ... have the tools to painlessly scan a patient,s troublesome mole ...
... have discovered a signaling pathway that is crucial to ... data, obtained from cells, animals and ALI patients, suggest ... the targets significantly reduced flooding of the lungs that ... is a devastating disease, with 40 percent mortality and ...
... Researchers at Memorial Sloan-Kettering Cancer Center,s Nanotechnology ... Hybrid Silica Technologies, have received approval for their ... US Food and Drug Administration (FDA) for an ... imaging of cancer, which may be useful for ...
... a patient,s immune system and enables them to fight the ... first time in the UK. The treatment will use ... of Southampton, which will treat a selected group of volunteers ... forms of bone marrow and blood cancer. Scientists ...
... MONDAY, Jan. 31 (HealthDay News) -- A man is much more ... another woman than a girlfriend who had sex with another man, ... to stick with a man who had sex with another woman ... The findings provide new insight into the general male desire to ...
... Sprint Fidelis implantable cardioverter-defibrillator (ICD) leads (Medtronic) failed more ... heart disease, according to a multicenter study published online ... that lead failure was not associated with death or ... the patients whose leads fractured experienced painful inappropriate shocks, ...
Cached Medicine News:Health News:Smart lasers could make cancer biopsies painless, help speed new drugs to market 2Health News:Researchers discover signaling pathway crucial to acute lung injury 2Health News:Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial 2Health News:Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial 3Health News:Southampton scientists begin patient trials of new leukemia cancer vaccine 2Health News:Southampton scientists begin patient trials of new leukemia cancer vaccine 3Health News:Recalled ICD leads fail in women, youths most often 2
... with obstructive sleep apnea necessitating tracheotomy, or ... Also indicated where airway access for pulmonary ... ,Another excellent choice for a sleep apnea ... series. Available with a low profile inner ...
... additional patient safety, the laryngectomy ... integral 15 mm ISO termination ... a ventilator, with or without ... , ,Portex® laryngectomy tubes ...
... nature of the silicone tube material allows ... and more comfort than tubes made of ... comfortable and compliant neck flange allows the ... irritation. A comprehensive range of sizes insures ...
... that in excess of 10% of all ... a specialized tracheostomy tube. Bivona® Fixed-Flange Hyperflex™ ... and can adapt to the unique anatomical ... extra horizontal length, extra vertical length, ...
Medicine Products: